These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 31911531)

  • 1. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.
    Krook MA; Lenyo A; Wilberding M; Barker H; Dantuono M; Bailey KM; Chen HZ; Reeser JW; Wing MR; Miya J; Samorodnitsky E; Smith AM; Dao T; Martin DM; Ciombor KK; Hays J; Freud AG; Roychowdhury S
    Mol Cancer Ther; 2020 Mar; 19(3):847-857. PubMed ID: 31911531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyclonal Secondary
    Goyal L; Saha SK; Liu LY; Siravegna G; Leshchiner I; Ahronian LG; Lennerz JK; Vu P; Deshpande V; Kambadakone A; Mussolin B; Reyes S; Henderson L; Sun JE; Van Seventer EE; Gurski JM; Baltschukat S; Schacher-Engstler B; Barys L; Stamm C; Furet P; Ryan DP; Stone JR; Iafrate AJ; Getz G; Porta DG; Tiedt R; Bardelli A; Juric D; Corcoran RB; Bardeesy N; Zhu AX
    Cancer Discov; 2017 Mar; 7(3):252-263. PubMed ID: 28034880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infigratinib in patients with advanced cholangiocarcinoma with
    Makawita S; K Abou-Alfa G; Roychowdhury S; Sadeghi S; Borbath I; Goyal L; Cohn A; Lamarca A; Oh DY; Macarulla T; T Shroff R; Howland M; Li A; Cho T; Pande A; Javle M
    Future Oncol; 2020 Oct; 16(30):2375-2384. PubMed ID: 32580579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
    Wang Y; Ding X; Wang S; Moser CD; Shaleh HM; Mohamed EA; Chaiteerakij R; Allotey LK; Chen G; Miyabe K; McNulty MS; Ndzengue A; Barr Fritcher EG; Knudson RA; Greipp PT; Clark KJ; Torbenson MS; Kipp BR; Zhou J; Barrett MT; Gustafson MP; Alberts SR; Borad MJ; Roberts LR
    Cancer Lett; 2016 Sep; 380(1):163-73. PubMed ID: 27216979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
    Goyal L; Shi L; Liu LY; Fece de la Cruz F; Lennerz JK; Raghavan S; Leschiner I; Elagina L; Siravegna G; Ng RWS; Vu P; Patra KC; Saha SK; Uppot RN; Arellano R; Reyes S; Sagara T; Otsuki S; Nadres B; Shahzade HA; Dey-Guha I; Fetter IJ; Baiev I; Van Seventer EE; Murphy JE; Ferrone CR; Tanabe KK; Deshpande V; Harding JJ; Yaeger R; Kelley RK; Bardelli A; Iafrate AJ; Hahn WC; Benes CH; Ting DT; Hirai H; Getz G; Juric D; Zhu AX; Corcoran RB; Bardeesy N
    Cancer Discov; 2019 Aug; 9(8):1064-1079. PubMed ID: 31109923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
    Javle M; Lowery M; Shroff RT; Weiss KH; Springfeld C; Borad MJ; Ramanathan RK; Goyal L; Sadeghi S; Macarulla T; El-Khoueiry A; Kelley RK; Borbath I; Choo SP; Oh DY; Philip PA; Chen LT; Reungwetwattana T; Van Cutsem E; Yeh KH; Ciombor K; Finn RS; Patel A; Sen S; Porter D; Isaacs R; Zhu AX; Abou-Alfa GK; Bekaii-Saab T
    J Clin Oncol; 2018 Jan; 36(3):276-282. PubMed ID: 29182496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
    DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
    J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas.
    Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S
    Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
    Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
    Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.
    Wu Q; Zhen Y; Shi L; Vu P; Greninger P; Adil R; Merritt J; Egan R; Wu MJ; Yin X; Ferrone CR; Deshpande V; Baiev I; Pinto CJ; McLoughlin DE; Walmsley CS; Stone JR; Gordan JD; Zhu AX; Juric D; Goyal L; Benes CH; Bardeesy N
    Cancer Discov; 2022 May; 12(5):1378-1395. PubMed ID: 35420673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
    King G; Javle M
    Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
    Kendre G; Marhenke S; Lorz G; Becker D; Reineke-Plaaß T; Poth T; Murugesan K; Kühnel F; Woller N; Wirtz RM; Pich A; Marquardt JU; Saborowski M; Vogel A; Saborowski A
    Hepatology; 2021 Sep; 74(3):1357-1370. PubMed ID: 33709535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.
    Wu Q; Ellis H; Siravegna G; Michel AG; Norden BL; Fece de la Cruz F; Balasooriya ER; Zhen Y; Silveira VS; Che J; Corcoran RB; Bardeesy N
    Clin Cancer Res; 2024 Jan; 30(1):198-208. PubMed ID: 37843855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion.
    Kawano S; Kawada MI; Fukushima S; Arai Y; Shibata T; Miyano SW
    Anticancer Res; 2024 Jun; 44(6):2393-2406. PubMed ID: 38821585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
    Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
    PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations.
    Varghese AM; Patel J; Janjigian YY; Meng F; Selcuklu SD; Iyer G; Houck-Loomis B; Harding JJ; O'Reilly EM; Abou-Alfa GK; Lowery MA; Berger MF
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.
    Botrus G; Raman P; Oliver T; Bekaii-Saab T
    Expert Opin Investig Drugs; 2021 Apr; 30(4):309-316. PubMed ID: 33307867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma.
    Ito Y; Yamada D; Kobayashi S; Sasaki K; Iwagami Y; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
    Cancer Lett; 2024 Jul; 595():216997. PubMed ID: 38801887
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Cleary JM; Raghavan S; Wu Q; Li YY; Spurr LF; Gupta HV; Rubinson DA; Fetter IJ; Hornick JL; Nowak JA; Siravegna G; Goyal L; Shi L; Brais LK; Loftus M; Shinagare AB; Abrams TA; Clancy TE; Wang J; Patel AK; Brichory F; Vaslin Chessex A; Sullivan RJ; Keller RB; Denning S; Hill ER; Shapiro GI; Pokorska-Bocci A; Zanna C; Ng K; Schrag D; Jänne PA; Hahn WC; Cherniack AD; Corcoran RB; Meyerson M; Daina A; Zoete V; Bardeesy N; Wolpin BM
    Cancer Discov; 2021 Oct; 11(10):2488-2505. PubMed ID: 33926920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.